PARIS (Reuters) -French drugmaker Sanofi and its British partner GlaxoSmithKline said on Wednesday they intend to submit data from their booster and Phase III efficacy trials as the basis for regulatory applications for a COVID-19 vaccine. “We’re very pleased with these data, which confirm our strong science and the benefits of our COVID-19 vaccine. The Sanofi-GSK vaccine demonstrates a universal ability to boost all platforms and across all ages,” said Thomas Triomphe, executive vice president for Sanofi Vaccines. The two companies had surprised investors at the end of December by delaying da…